Sort
82,697 grants matching “vaccine development”
Development of a Vaccine for HIV-AIDS: Humoral Immunity
$3,148,210Marjorie Robert-Guroff · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Human Dendritic Cells and In Vivo Immunity to Biothreat
$3,148,010Jacques F Banchereau · Baylor Research Institute · U19 · FY2006 · AI
Tuberculosis Imaging Program
$3,147,878Steven Holland · National Institute Of Allergy And Infectious Diseases · ZIC · FY2024 · AI
Shared Resource Management
$3,146,547M. Celeste Simon · University Of Pennsylvania · P30 · FY2025 · CA
Yellow Fever, rDNA (EP+IL-12) and rAd35 as Vectors for AIDS Vaccine Development
$3,146,402David I Watkins · University Of Miami School Of Medicine · P01 · FY2016 · AI
Cellular Immunity to Category A-C Viruses in Humans
$3,143,817Robert William Finberg · Univ Of Massachusetts Med Sch Worcester · U19 · FY2012 · AI
Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP-COVID)
$3,143,795Eugene M. Oltz · Ohio State University · U54 · FY2023 · CA
Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis
$3,143,754Jerrold J. Ellner · Boston Medical Center · U19 · FY2014 · AI
Structure-function studies of alpha-and flaviviruses
$3,142,993Richard J. Kuhn · Purdue University · P01 · FY2006 · AI
Structure-function studies of alpha-and flaviviruses
$3,142,721Richard J. Kuhn · Purdue University · P01 · FY2007 · AI
TCR Gene Modified T Cells for Adoptive Immunotherapy
$3,141,645Michael I Nishimura · Loyola University Chicago · P01 · FY2013 · CA
Human Dendritic Cells and In Vivo Immunity to Biothreat
$3,141,637Jacques F Banchereau · Baylor Research Institute · U19 · FY2007 · AI
Human Dendritic Cells and In Vivo Immunity to Biothreat
$3,141,637Jacques F Banchereau · Baylor Research Institute · U19 · FY2008 · AI
Case AIDS Clinical Trials Unit
$3,140,238Michael Marcel Lederman · Case Western Reserve University · U01 · FY2011 · AI
NIAID VIROLOGY QUALITY ASSURANCE
$3,136,915James Bremer · Rush University Medical Center · N01 · FY2016 · AI
Emory-CDC CTU
$3,134,849Jeffrey Lennox · Emory University · UM1 · FY2021 · AI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders
$3,134,725William Childs · National Heart, Lung, And Blood Institute · ZIA · FY2017 · HL
Fast-Track Production of a Heptavalent Botulinum Vaccine
$3,134,091Dynport Vaccine Company, Llc · U01 · FY2004 · AI
Development of a recombinant trimeric RSV-F vaccine (DS-Cav1)
$3,132,917Richard Schwartz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Partners Healthcare Systems/Harvard Medical School/Boston Medical Center AIDS CTU
$3,132,349Daniel R Kuritzkes · Massachusetts General Hospital · U01 · FY2009 · AI
SPORE in Prostate Cancer
$3,131,870Sloan-Kettering Institute For Cancer Res · P50 · FY2003 · CA
Protective Mechanisms Against Pandemic Respiratory Virus
$3,126,720Stanford University · U19 · FY2004 · AI
NIAID SPECIMEN REPOSITORY
$3,126,511Kiersten Greenfield · Precision Bioservices, Inc. · N01 · FY2014 · AI
Optimizing anti-microbial immunity by targeting Sts-1
$3,125,627Nicholas A Carpino · State University New York Stony Brook · R01 · FY2025 · AI
Influenza responses and repertoire in vaccination, infection and tonsil organoids.
$3,125,022Mark M Davis · Stanford University · U19 · FY2020 · AI